Friday, July 10, 2026

Drug profile · INN

recombinant adsorbed bivalent human papillomavirus-like particle vaccine (derived from trichoplusia ni cell)

recombinant adsorbed bivalent human papillomavirus-like particle vaccine (derived from trichoplusia ni cell) (CERVARIX) is a biological vaccine - induces immune response.

PMDA: approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — recombinant adsorbed bivalent human papillomavirus-like particle vaccine (derived from trichoplusia ni cell)
Class
Route
Patents
0
Programs
3
Data quality
0.78

Quick answer

recombinant adsorbed bivalent human papillomavirus-like particle vaccine (derived from trichoplusia ni cell) (CERVARIX) is a biological vaccine - induces immune response.

Key facts

INN recombinant adsorbed bivalent human papillomavirus-like particle vaccine (derived from trichoplusia ni cell)
Brand CERVARIX
Mechanism Biological vaccine - induces immune response

Mechanism of action

Biological vaccine - induces immune response

Approval history

Authority Status Date
PMDA approved

Pipeline programs

  1. Cervarix™ Phase 3 · GSK Glaxo Smith · Infections, Papillomavirus
  2. PRO-EV71CA16-3001 Phase 3 · Sinovac Research and · Hand, Foot, and Mouth Disease(HFMD)
  3. Bivalent killed oral cholera vaccine Phase 2 · International Peace Maternity · Cholera

Frequently asked questions

What is recombinant adsorbed bivalent human papillomavirus-like particle vaccine (derived from trichoplusia ni cell)?

recombinant adsorbed bivalent human papillomavirus-like particle vaccine (derived from trichoplusia ni cell) (CERVARIX) is a biological vaccine - induces immune response.

What is the brand name for recombinant adsorbed bivalent human papillomavirus-like particle vaccine (derived from trichoplusia ni cell)?

CERVARIX is a marketed brand name for recombinant adsorbed bivalent human papillomavirus-like particle vaccine (derived from trichoplusia ni cell). Check FDA Drugs@FDA for the current US label holder and prescribing information.